Australia - English - Department of Health (Therapeutic Goods Administration)

clinect pty ltd - ribavirin, quantity: 200 mg - tablet, film coated - excipient ingredients: povidone; croscarmellose sodium; microcrystalline cellulose; crospovidone; silicon dioxide; magnesium stearate; titanium dioxide; macrogol 8000; hypromellose; purified talc - ibavyr (ribavirin tablets) is indicated in combination with other oral agents for the treatment of chronic hepatitis c (chc) in adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - sulfasalazine, quantity: 500 mg - tablet, enteric coated - excipient ingredients: white beeswax; propylene glycol; magnesium stearate; colloidal anhydrous silica; cellacefate; purified talc; macrogol 20000; povidone; carnauba wax; maize starch; glyceryl monostearate - ulcerative colitis and crohn's disease: adjunct in the treatment of ulcerative colitis with the usual supportive and dietary measures. for the management of severe, acute attacks of ulcerative colitis, rectal and systemic corticosteroid therapy appears to be clinically superior to sulfasalazine, but sulfasalazine may be more effective than corticosteroids in reducing the number of relapses in patients on maintenance therapy. in the treatment of active crohn's disease, especially in patients with colonic involvement. rheumatoid arthritis: pyralin en tablets are indicated for rheumatoid arthritis which has failed to respond to non-steroidal anti-inflammatory drugs (nsaids).

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - metoclopramide hydrochloride monohydrate, quantity: 10.5 mg (equivalent: metoclopramide hydrochloride, qty 10 mg) - tablet, uncoated - excipient ingredients: pregelatinised maize starch; colloidal anhydrous silica; lactose; magnesium stearate; microcrystalline cellulose - indications as at 18 december 2001: as an adjunct to x-ray examination of the stomach and duodenum. to assist in intestinal intubation. to control nausea and vomiting associated with the following conditions: intolerance to essential drugs possessing emetic properties (such as cytotoxic agents); uraemia, radiation sickness, malignant disease, post-operative vomiting, labour, infectious diseases. there is no clear benefit in motion sickness or other labyrinth disturbances. metoclopramide has been found useful in the management of gastric retention after gastric surgery; of diabetic gastroparesis of mild to moderate severity. once control of diabetes is established by diet and/or insulin, use of metoclopramide should be discontinued.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - doxepin hydrochloride, quantity: 56.5 mg (equivalent: doxepin, qty 50 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; hypromellose; lactose monohydrate; carnauba wax; purified talc; sodium starch glycollate; diethyl phthalate; magnesium stearate; titanium dioxide; indigo carmine; erythrosine; povidone - the 50mg and 75mg tablets are indicated only for the maintenance treatment of major depression. (see precautions).

Singapore - English - HSA (Health Sciences Authority)

pfizer private limited - varenicline tartrate 1.71 mg eqv. varenicline - tablet, film coated - 1 mg/tablet - varenicline tartrate 1.71 mg eqv. varenicline 1 mg/tablet

Singapore - English - HSA (Health Sciences Authority)

pfizer private limited - (light blue tablet) varenicline tartrate 1.71 mg eqv varenicline; (white tablet) varenicline tartrate 0.85 mg eqv varenicline - tablet, film coated - 0.5 mg - (light blue tablet) varenicline tartrate 1.71 mg eqv varenicline 1 mg; (white tablet) varenicline tartrate 0.85 mg eqv varenicline 0.5 mg

Singapore - English - HSA (Health Sciences Authority)

abbott laboratories (singapore ) private limited - dydrogesterone, micronized (in grey tablet); estradiol hemihydrate 1.03 mg eqv estradiol (micronised) (in grey tablet); estradiol hemihydrate 1.03 mg eqv estradiol (micronised) (in white tablet) - tablet, film coated - 10 mg - dydrogesterone, micronized (in grey tablet) 10 mg; estradiol hemihydrate 1.03 mg eqv estradiol (micronised) (in grey tablet) 1 mg; estradiol hemihydrate 1.03 mg eqv estradiol (micronised) (in white tablet) 1 mg

Singapore - English - HSA (Health Sciences Authority)

novo nordisk pharma (singapore) pte ltd - (blue tablet) estradiol hemihydrate 2.07mg equivalent to; (red tablet) estradiol hemihydrate 1.03mg equivalent to; (white tablet) estradiol as hemihydrate 2.07mg equivalent to; (white tablet) norethisterone acetate - tablet, film coated - 2 mg - (blue tablet) estradiol hemihydrate 2.07mg equivalent to 2 mg; (red tablet) estradiol hemihydrate 1.03mg equivalent to 1 mg; (white tablet) estradiol as hemihydrate 2.07mg equivalent to 2 mg; (white tablet) norethisterone acetate 1 mg

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - dosulepin (dothiepin) hydrochloride, quantity: 75 mg - tablet, film coated - excipient ingredients: povidone; maize starch; sodium starch glycollate; lactose monohydrate; purified talc; magnesium stearate; titanium dioxide; xanthan gum; polyvinyl alcohol; brilliant scarlet 4r; lecithin - the 75mg tablets are indicated only for the maintenance treatment of major depression. (see precautions).

Australia - English - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - amoxicillin trihydrate, quantity: 1004.31 mg; potassium clavulanate, quantity: 151.917 mg - tablet, film coated - excipient ingredients: magnesium stearate; colloidal anhydrous silica; dichloromethane; microcrystalline cellulose; sodium starch glycollate; isopropyl alcohol; titanium dioxide; hypromellose; propylene glycol; purified talc; ethylcellulose - amclavox duo forte 875/125 tablets are indicated for short-term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to microbiology):,urinary tract infections (complicated and uncomplicated),lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis,upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis.,skin and skin structure infection.,appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to amoxicillin and clavulanic acid tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections caused by amoxicillin susceptible organisms and beta-lactamase producing organisms susceptible to amoxicillin and clavulanic acid tablets preparations should not require the addition of another antibiotic due to the amoxicillin content of these products.